Natural Modulators of Estrogen Biosynthesis and Function as Chemopreventive Agents

Archives of Pharmacal Research

Volumn 24, Issue 6, 2001, Pages 473-484

  Bhat, Krishna P L ^a   Pezzuto, John M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antiestrogens; Aromatase inhibition; Breast cancer; Natural products; Sulfatase inhibition

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ENZYME INHIBITOR; ESTROGEN; ESTRONE SULFATASE; ISOFLAVONE DERIVATIVE; PHYTOESTROGEN; PLANT MEDICINAL PRODUCT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SULFATASE;

BREAST TUMOR; DRUG ANTAGONISM; FEMALE; HUMAN; REVIEW;

ANTICARCINOGENIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGENS, NON-STEROIDAL; FEMALE; HUMANS; ISOFLAVONES; PHYTOESTROGENS; PLANT PREPARATIONS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SULFATASES;

EID: 0035755189     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02975150     Document Type: Article

References (118)

1. Adlercreutz, H., Phytoestrogens: epidemiology and a possible role in cancer protection. Environ. Health Perspect., 103, 103-112 (1995).
2. Adlercreutz, H., Gorbach, S. L., Goldin, B. R., Woods, M. N., Dwyer, J. T., and Hamalainen, E., Estrogen metabolism and excretion in Oriental and Caucasian women. J. Natl. Cancer Inst., 86, 1076-1082 (1994).
3. Adlercreutz, H., Hamalainen, E., Gorbach, S., and Goldin, B., Dietary phyto-oestrogens and the menopause in Japan. Lancet, 339, 1233 (1992).
4. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., and Fukami, Y., Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem., 262, 5592-5595 (1987).
5. Albert, J. L., Sundstrom, S. A., and Lyttle, C. R., Estrogen regulation of placental alkaline phosphatase gene expression in a human endometrial adenocarcinoma cell line. Cancer Res., 50, 3306-3310 (1990).
6. Anzai, Y, Holinka, C. F., Kuramoto, H., and Gurpide, E., Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res., 49, 2362-2365 (1989).
7. Barnes, S., The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res. Treat., 46, 169-179 (1997).
8. Bennetts, H. W., Underwood, E. J., and Shier, F. L., A specific breeding problem of sheep on subterranean clover pastures in western Australia. Aus. Vet. J., 22, 2-12 (1946).
9. Bhat, K. R. L., Lantvit, D., Christov, K., Mehta, R. G., Moon, R. C., and Pezzuto, J. M., Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res., 61, 7456-7463 (2001).
10. Bhat, K. P. L. and Pezzuto, J. M., Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res., 61, 6137-6144 (2001).
11. Bolton, J. L., Trush, M. A., Penning, T. M., Dryhurst, G., and Monks, T. J., Role of quinones in toxicology. Chem. Res. Toxicol., 13, 135-160 (2000).
12. Brueggemeier, R. W., Biochemical and molecular aspects of aromatase. J. Enzyme Inhib., 4, 101-111 (1990).
13. Brzezinski, A. and Debi, A., Phytoestrogens: the "natural" selective estrogen receptor modulators? Eur. J. Obstet. Gynecol. Reprod. Biol., 85, 47-51 (1999).
14. Canick, J. A. and Ryan, K. J., Cytochrome P-450 and the aromatization of 16alpha-hydroxytestosterone and androstenedione by human placental microsomes. Mol. Cell. Endocrinol., 6, 105-115 (1976).
15. Carusi, D., Phytoestrogens as hormone replacement therapy: an evidence-based approach. Prim. Care Update Ob. Gyns., 7, 253-259 (2000).
16. Chen, Y., Liu, X., Pisha, E., Constantinou, A. I., Hua, Y, Shen, L., van Breemen, R. B., Elguindi, E. C., Blond, S. Y., Zhang, F., and Bolton, J. L., A metabolite of equine estrogens, 4-hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines. Chem. Res. Toxixol., 13, 342-350 (2000).
17. Chilvers, C., Mant, D., and Pike, M. C., Cervical adenocarcinoma and oral contraceptives. Br. Med. J., 295, 1446-1447 (1987).
18. Chu, G. H., Peters, A., Selcer, K. W., and Li, P. K., Synthesis and sulfatase inhibitory activities of (E)- and (Z)4-hydroxytamoxifen sulfamates. Bioorg. Med. Chem. Lett., 9, 141-144, 1999.
19. Curtis Hewitt, S., Couse, J. F., and Korach, K. S., Estrogen receptor transcription and transactivation: Estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res., 2, 345-352 (2000).
20. Dardes, R. C. and Jordan, V. C., Novel agents to modulate oestrogen action. Br. Med. Bull., 56, 773-786 (2000).
21. Davidai, G., Lee, A., Schvartz, I., and Hazum, E., PDCF induces tyrosine phosphorylation in osteoblast-like cells: relevance to mitogenesis. Am. J. Physiol., 263, E205-209 (1992).
22. De Coster, R., Van Ginckel, R. F, Callens, M. J., Goeminne, N. K., and Janssens, B. L., Antitumoral and endocrine effects of (+)-vorozole in rats bearing dirnethylbenzanthracene-induced mammary tumors. Cancer Res., 52, 1240-1244 (1992).
23. Dees, C., Foster, J. S., Ahamed, S., and Wimalasena, J., Dietary estrogens stimulate human breast cells to enter the cell cycle. Environ. Health Perspect., 105, 633-636 (1997).
24. Di Salle, E., Giudici, D., Ornati, G., Briatico, G., DAlessio, R., Villa, V. and Lombardi, R., 4-Aminoandrostenedione derivatives: a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione. J. Steroid Biochem. Mol. Biol., 37, 369-374 (1990).
25. Duncan, L., Purohit, A., Howarth, N. M., Potter, B. V., and Reed, M. J., Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer. Cancer Res., 53, 298-303 (1993).
26. Es-Saady, D., Simon, A., Jayat-Vignoles, C., Chulia, A. J., and Delage, C. MCF-7 cell cycle arrested at G1 through ursolic acid, and increased reduction of tetrazolium salts. Anticancer Res., 16, 481-486 (1996).
27. Evans, B. A., Griffiths, K., and Morton, M. S., Inhibition of 5-alpha-reductase in genital skin fibroblaste and prostate tissue by dietary lignans and isoflavonoids. J. Endochnol., 147, 295-302 (1995).
28. Fournier, D. B., Erdman, J. W. Jr., and Gordon, G. B.: Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data. Cancer Epidemiol. Biomarkers Prev., 7, 1055-1065 (1998).
29. Fujimoto, J., Hori, M., Ichigo, S., Hirose, R., and Tamaya, T., Antiestrogenic compounds inhibit estrogen-induced expressions of basic fibroblast growth factor and its mRNA in well-differentiated endometrial cancer cells. Gen. Pharmacol., 28, 215-219 (1997).
30. Fujimoto, J., Hori, M., Ichigo, S., Morishita, S., and Tamaya, T., Estrogen induces expression of c-fos and c-jun via activation of protein kinase C in an endometrial cancer cell line and fibroblasts derived from human uterine endometrium. Gynecol. Endocrinol., 10, 109-118 (1996).
31. Fujimoto, J., Sakaguchi, H., Hirose, R., Ichigo, S., and Tamaya, T., Progestins suppress estrogen-induced expression of vascular endothelial growth factor (VEGF) subtypes in uterine endometrial cancer cells. Cancer Lett., 141, 63-71 (1999).
32. Fuqua, S. A., Russo, J., Shackney, S. E., and Stearns, M. E., Selective estrogen receptor modulators. An aid in unraveling the links between estrogen and breast cancer. Postgrad. Med., 35, 3-10 (2001).
33. Gal, D., Forney, J. P., Dev, V. G., and Porter, J. C., A new human cell line derived from a poorly differentiated endometrial adenocarcinoma. Cynecol. Oncol., 13, 50-57 (1982).
34. GOSS, P. E. and Gwyn, K. M., Current perspectives on aromatase inhibitors in breast cancer. J. Clin. Oncol., 12, 2460-2470 (1994).
35. Gravanis, A. and Gurpide, E., Effects of estradiol on deoxyribonucleic acid polymerase alpha activity in the Ishikawa human endometrial adenocarcinoma cell line. J. Clin. Endocrinol. Metab., 63, 356-359 (1986).
36. Greenwald, P., Barlow, J. J., Nasca, P. C., and Burnett, W. S., Vaginal cancer after maternal treatment with synthetic estrogens. N. Engl. J. Med., 285, 390-392 (1971).
37. Guzman, R. C., Yang, J., Rajkumar, L., Thordarson, G., Chen, X., and Nandi, S.: Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. Proc. Natl. Acad. Sci. USA, 96, 2520-2525 (1999).
38. Hata, H. and Kuramoto, H., Immunocytochemical determination of estrogen and progesterone receptors in human endometrial adenocarcinoma cells (Ishikawa cells). J. Steroid Biochem. Mol. Biol., 42, 201-210 (1990).
39. Henderson, D., Habenicht, U. F., Nishino, Y., and el Etreby, M. F., Estrogens and benign prostatic hyperplasia: the basis for aromatase inhibitor therapy. Steroids, 50, 219-233 (1987).
40. Henderson, B. E., Ross, R., and Bernstein, L., Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res., 48, 246-253 (1988).
41. Herbst, A. L., Clear cell adenocarcinoma and the current status of DES-exposed females. Cancer, 8, 484-488 (1981).
42. Hobkirk, R., Steroid sulfotransferases and steroid sulfate sulfatases: characteristics and biological roles. Can. J. Biochem. Cell Biol., 63, 1127-1144 (1985).
43. Holinka, C. F., Hata, H., Kuramoto, H., and Gurpide, E., Responses to estradiol in a human endometrial adenocarcinoma cell line (Ishikawa). J. Steroid Biochem., 24, 85-89 (1986).
44. Howarth, N. M., Purohit, A., Reed, M. J., and Potter, B. V., Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem., 37, 219-221 (1994).
45. Hsieh, C. Y., Santell, R. C., Haslam, S. Z., and Helferich, W. C., Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res., 58, 3833-3838 (1998).
46. Huang, M. -T., Ho, C. -T., Wang, Z. Y., Ferraro, T., Lou, Y. R., Stauber, K., Ma, W., Georgiadis, C., Laskin, J. D., and Conney, A. H., Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res., 54, 701-708 (1994).
47. Jang, M., Cai, L, Udeani, G. O., Slowing, K. V, Thomas, C. F., Beecher, C. W., Fong, H. H., Farnsworth, N, R., Kinghorn, A. D., Mehta, R. G., Moon, R. C., and Pezzuto, J. M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218-220 (1997).
48. Jeong, H. -J., Chang, L. C., Kim, J. -K., Kim, I. -K., Kinghorn, A. D., and Pezzuto, J. M. Aromatase inhibitors from Isodon excisus var. coreanus. Arch. Pharmacal Res., 23, 243-245 (2000).
49. Jordan, V. C., Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer, 12, 419-424 (1976).
50. Katzenellenbogen, B. S., Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol. Reprod., 54, 287-293 (1996).
51. Katzenellenbogen, B. S., Choi, I., Delage-Mourroux, R., Ediger, T. R., Martini, R. G., Montano, M., Sun, J., Weis, K., and Katzenellenbogen, J. A., Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J. Steroid Biochem. Mol. Biol., 74, 279-285 (2000).
52. Katzenellenbogen, B. S., Montano, M. M., Ekena, K., Herman, M. E. and McInerney, E. M., William L. Mc Guire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res. Treat., 44, 23-38 (1997).
53. Kauppila, A., Changing concepts of medical treatment of endometriosis. Acta Obstet. Gynecol. Scand., 72, 324-336 (1993).
54. Kawase, T., Orikasa, M., Ogata, S., and Burns, D.M., Protein tyrosine phosphorylation induced by epidermal growth factor and insulin-like growth factor-I in a rat clonal dental pulp-cell line. Arch. Oral Biol., 40, 921-929 (1995).
55. Kellis, J. T. Jr., and Vickery, L. E. Purification and characterization of human placental aromatase cytochrome P-450. J. Biol. Chem., 262, 4413-4420 (1987).
56. Kelloff, G. J., Lubet, R. A., Lieberman, R., Eisenhauer, K., Steele, V. E., Crowell, J. A., Hawk, E. T., Boone, C. W., and Sigman, C. C., Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prev., 7, 65-78 (1998).
57. Kitawaki, J., Kim, T., Kanno, H., Noguchi, T., Yamamoto, T., and Okada, H., Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: a new system for aromatase inhibitor screening. J. Steroid. Biochem. Mol. Biol., 44, 667-670 (1993).
58. Ko, H. H., Yu, S. M., Ko, F. N., Teng, C. M. and Lin, C. N., Bioactive constituents of Morus australis and Broussonetia papyrifera. J. Nat. Prod., 60, 1008-1011 (1997).
59. Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S. and Gustafsson, J. A., Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA, 93, 5925-5930 (1996).
60. Lamartiniere, C. A., Zhang, J. X., and Cotroneo, M. S., Genistein studies in rats: potential for breast cancer prevention and reproductive and developmental toxicity. Am. J. Clin. Nutr., 68, 1400S-1405S (1998).
61. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A., Cancer statistics. C.A Cancer J. Clin., 49, 8-31 (1999).
62. Le Bail, J. C., Varnat, F., Nicolas, J. C., and Habrioux, G., Estrogenic and antiproliferative activities on MCF-7 human breast cancer cells by flavonoids. Cancer Lett., 130, 209-216 (1998).
63. Lee, D., Bhat, K. P. L., Fong, H. H. S., Farnsworth, N. R., Pezzuto, J. M., and Kinghorn, A. D., Aromatase inhibitors from Broussonetia papyrifera. J. Nat. Prod., ?, 1286-1293 (2001).
64. Lerner L. J. and Jordan, V. C., Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res., 50, 4177-4189 (1990).
65. Lessey, B. A., Ilesanmi, A. O., Castelbaum, A. J., Yuan, L., Somkuti, S. G., Chwalisz, K., and Satyaswaroop, P. G., Characterization of the functional progesterone receptor in an endometrial adenocarcinoma cell line (Ishikawa): progesterone-induced expression of the alphal integrin. J. Steroid Biochem. Mol. Biol., 59, 31-39 (1996).
66. Liehr, J. G., Ulubelen, A. A., and Strobel, H. W., Cytochrome P-450-mediated redox cycling of estrogens. J. Biol. Chem., 261, 16865-16870 (1986).
67. Lindahl, B., Aim, P., Ferno, M., Norgren, A., and Trope, C., Plasma steroid hormones, cytosol receptors, and thymidine incorporation rate in endometrial carcinoma. Am. J. Obstet. Cynecol., 149, 607-612 (1984).
68. Lissin, L. W. and Cooke, J. P., Phytoestrogens and cardiovascular health. J. Am. Coll. Cardiol., 35, 1403-1410 (2000).
69. Littlefield, B. A., Gurpide, E., Markiewicz, L., McKinley, B., and Hochberg, R. B., A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of delta 5 adrenal steroids. Endocrinology, 127, 2757-2762 (1990).
70. Lubet, R. A., Steele, V. E., Casebolt, T. L., Eto, I., Kelloff, G. J., and Grubbs, C. J., Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis, 15, 2775-2780 (1994).
71. MacGregor, J, I. and Jordan, V. C., Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev., 50, 151-196 (1998).
72. MacIndoe, J. H., The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells. Endocrinology, 123, 1281-1287 (1988).
73. Makela, S., Davis, V. L., Tally, W. C., Korkman, J., Salo, L., Vihko, R., Santti, R., and Korach, K.S., Dietary estrogens act through estrogen receptor-mediated processes and show no antiestrogenicity in cultured breast cancer cells. Environ. Health Perspect, 102, 572-578 (1994).
74. Manez, S., Recio, M. C., Giner, R. M., and Rios, J. L., Effect of selected triterpenoids on chronic dermal inflammation, fur. J. Pharmacol., 334, 103-105 (1997).
75. Manni, A. and Wright, C., Effect of tamoxifen and α-difluoromethylornithine on clones of nitrosomethylurea-induced rat mammary tumor cells grown in soft agar culture. Cancer Res., 43, 1084-1086 (1983).
76. Masamura, S., Santner, S. J., and Santen, R. J., Evidence of in situ estrogen synthesis in nitrosomethylurea-induced rat mammary tumors via the enzyme estrone sulfatase. J. Steroid. Biochem. Mol. Biol., 58, 425-429 (1996).
77. McMichael-Phillips, D. F., Harding, C., Morton, M., Roberts, S. A., Howell, A., Rotten, C. S., and Bundred, N. J., Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am. J. Clin. Nutr., 68, 1431S-1435S (1999).
78. Metzger, D., White, J. H., and Chambon, P., The human oestrogen receptor functions in yeast. Nature, 334, 31-36 (1988).
79. Moon, R. C., Steele, V. E., Kelloff, G. J., Thomas, C. F., Detrisac, C. J., Mehta, R. G., and Lubet, R. A., Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone. Anti-cancer Res., 14, 889-893 (1994).
80. Moorghen, M., Orde, M., Finney, K. J., Appleton, D. R., and Watson, A. J., Sulindac enhances cell proliferation in DMH-treated mouse colonic mucosa. Cell Prolif., 31, 59-70 (1998).
81. Nandi, S., Guzman, R. C., and Yang, J., Hormones and mammary carcinogenesis in mice, rats and humans: a unifying hypothesis. Proc. Natl. Acad. Sci. USA, 92, 3650-3657 (1995).
82. Nguyen, B. -L., Ferme, I., Chetrittte, G., and Pasqualini, J. R., Action of danazol on the conversion of estrone sulfate to estradiol and on the sulfatase activity in the MCF-7, T-47D and MDA-MB-231 human mammary cancer cells. J. Steroid Biochem. Molec. Biol., 46, 17-23 (1993).
83. Nishida, M., Kasahara, K., Kaneko, M., Iwasaki, H., and Hayashi, K., Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nippon Sanka Fujinka Cakkai Zasshi, 37, 1103-1111 (1985).
84. Nissen, E. D. and Kent, D. R., Liver tumors and oral contraceptives. Obstet. Gynecol., 46, 460-467 (1975).
85. Paik, K. J., Jeon, S. S., Chung, H. Y, Lee, K. H., Kim, K. W, Chung, J. K., and Kim, N. D., Induction of differentiation of the cultured rat mammary epithelial cells by triterpene acids. Arch. Pharm. Res., 21, 398-405 (1998).
86. Pasqualini, J. R., Chetrite, G., and Nestour, E. L., Control and expression of oestrone sulphatase activities in human breast cancer. J. Endocrinol., 150, S99-105 (1996).
87. Pham, T. A., Hwung, Y. P., Santiso-Mere, D., McDonnell, D. P., and O'Malley, B. W., Ligand-dependent and -independent function of the transactivation regions of the human estrogen receptor in yeast. Mol. Endocrinol., 6: 1043-1050, (1992).
88. Pisha, E. and Pezzuto, J. M., Cell-based assay for the determination of estrogenic and anti-estrogenic activities. Meth. Cell Science, 19, 37-43 (1997).
89. Pisha, E., Lui, X., Constantinou, A. I., and Bolton, J. L., Evidence that a metabolite of equine estrogens, 4-hydroxyequilenin, induces cellular transformation in vitro. Chem. Res. Toxicol. 14, 82-90 (2001).
90. Purohit, A., Williams, G. J., Howarth, N. M., Potter, B. V., and Reed, M. J. Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate. Biochemistry, 34, 11508-11514 (1995).
91. Purohit, A., Woo, L. W., Barrow, D., Hejaz, H. A., Nicholson, R. I., Potter, B. V., and Reed, M. J. Nonsteroidal and steroidal sulfamates: new drugs for cancer therapy. Mol. Cell. Endocrinol., 171, 129-135 (2001).
92. Purohit, A., Woo, L. W., Singh, A., Winterborn, C. J., Potter, B. V., and Reed, M. J., In vivo activity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor. Cancer Res., 56, 4950-4955 (1996).
93. Reddy, P., A review of the newer aromatase inhibitors in the management of metastatic breast cancer. J. Clin. Pharm. Ther., 23, 81-90 (1998).
94. Reed, M. J., Lai, L. C., Owen, A. M., Singh, A., Coldham, N. G., Purohit, A., Ghilchik, M. W., Shaikh, N. A., and James, V. H., Effect of treatment with 4-hydroxyandro stenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer. Cancer Res., 50, 193-196 (1990).
95. Rose, D. P., Boyer, A. R., and Wynder, E. L., International comparison of mortality rates for cancer of the breast, ovary, prostate and colon, per capita fat consumption. Cancer, 58, 2363-2371 (1986).
96. Ruder, H. J., Loriaux, L., and Lipsett, M. B., Estrone sulfate: production rate and metabolism in man. J. Clin. Invest., 51, 1020-1033 (1972).
97. Santen, R. J., Leszczynski, D., Tilson-Mallet, N., Feil, P. D., Wright, G., Manni, A., and Santner, S. J., Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. Ann. N. Y. Acad. Sci., 464, 126-137 (1986).
98. Santner, S. J., Feil, P. D., and Santen, R. J., In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J. Clin. Endocrinol., 59, 29-33 (1984).
99. Shao, Z. M., Wu, J., Shen, Z. Z., and Barsky, S. H. Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res., 58, 4851-4857 (1998).
100. Shaw R. W., Adverse long-term effects of oral contraceptives: a review. Br. J. Obstet. Gynaecol., 94, 724-730 (1987).
101. Simard, J., Sanchez, R., Poirier, D., Gauthier, S., Singh, S. M., Merand, Y, Belanger, A., Labrie, C., and Labrie, F., Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res., 57, 3494-3497 (1997).
102. Song, L. L., Kosmeder, J. W. II, Lee, S. K., Gerhäuser, C., Lantvit, D., Moon, R. C., Moriarty, R. M., and Pezzuto, J. M., Cancer chemopreventive activity mediated by 4′-bromoflavone, a potent inducer of phase II detoxification enzymes. Cancer Res., 59, 578-585 (1999).
103. Soto, A. M., Sonnenschein, C., Chung, K. L., Fernandez, M. F., Olea, N., and Serrano, F. O., The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. Environ. Health Perspect., 103, 113-122, (1995).
104. Subbaramaiah, K., Michaluart, P., Sporn, M. B., and Dannenberg, A. J., Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Cancer Res., 60, 2399-2404 (2000).
105. Tsutsui, T. and Barrett, J. C., Neoplastic transformation of cultured mammalian cells by estrogens and estrogen like chemicals. Environ. Health Perspect., 105, 619-624 (1997).
106. Uesugi, T., Toda, T., Tsuji, K., and Ishida, H., Comparative study on reduction of bone loss and lipid metabolism abnormality in ovariectomized rats by soy isoflavones, daidzin, genistin, and glycitin. Biol. Pharm. Bull., 24, 368-372 (2001).
107. Vogel, C. L., Hormonal approaches to breast cancer treatment and prevention: an overview. Semin. Oncol., 23, 2-9 (1996).
108. Wang, C. and Kurzer, M. S., Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr. Cancer, 28: 236-247 (1997).
109. Wang, T. T., Sathyamoorthy, N., and Phang, J. M. Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis, 17, 271-275 (1996).
110. Whitten, P. L., Russell, E., and Naftolin, F., Effects of a normal, human-concentration, phytoestrogen diet on rat uterine growth. Steroids, 57, 98-106 (1992).
111. Yamamoto, T., Kitawaki, J., Urabe, M., Honjo, H., Tamura, T., Noguchi, T., Okada, H., Sasaki, H., Tada, A., and Terashima, Y., Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells. J. Steroid Biochem. Mol. Biol., 44, 463-468 (1993).
112. Yamamoto, Y., Urabe, M., Tamura, T., Kitawaki, J., Honjo, H., and Okada, H., Antitumor effect of pyridoglutethimide, an aromatase inhibitor, on 7,12-dimethylbenz (a)anthracene-induced mammary tumors of rat. Anti-cancer Res., 11, 1999-2002 (1991).
113. Yan, Z. J. and Roy, D., Mutations in DNA polymerase beta mRNA of stilbene estrogen-induced kidney tumors in Syrian hamster. Biochem. Mol. Biol. Int., 37, 175-183 (1995).
114. Yue, W., Zhou, D., Chen, S., and Brodie, A., A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res., 54, 5092-5095 (1994).
115. Zaccheo, T., Ciudici, D., Ornati, C., Panzeri, A., and di Salle, E., Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours. Eur. J. Cancer, 27, 1145-1150 (1991).
116. Zajchowski, D.A., Kauser, K., Zhu, D., Webster, L., Aberle, S., White, F. A. III, Liu, H. L., Humm, R., MacRobbie, J., Ponte, P., Hegele-Hartung, C., Knauthe, R., Fritzemeier, K. H., Vergona, R., and Rubanyi, C. M., Identification of selective estrogen receptor modulators by their gene expression fingerprints. J. Biol. Chem., 275, 15885-15894 (2000).
117. Zhou, D. J., Pompon, D., and Chen, S. A., Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res., 50, 6949-6954 (1990).
118. Zhou, J. R., Mukherjee, P., Cugger, E. T., Tanaka, T., Blackburn, G. L., and Clinton, S. K., Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res., 58, 5231-5238, (1998).